Tilarginine

DB11815ApprovedInvestigationalWithdrawnSmall molecule

Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.

Mechanism: Pharmacologically active on Nitric oxide synthase
Curator reviewed
Formula / weight: C₇H₁₆N₄O₂ · 188.2275 g/mol (avg)
Also known as: L-Monomethylarginine · L-Ng-monomethyl Arginine · L-NMMA · N-Methylarginine · N(G)-Methylarginine

Resolves to

Compound

UNII27JT06E6GRCAS17035-90-4ChEMBLCHEMBL256147ChEBI60257PubChem132862KEGGC03884

Structure

InChIKeyNTNWOCRCBQPEKQ-YFKPBYRVSA-NSMILESCNC(=N)NCCC[C@H](N)C(O)=O

Targets

P29474NOS3

What you can answer from here — as of September 19, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

45Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tilarginine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account